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Abstract
To gain a better understanding of the underlying mechanisms of neurological disease, relevant
tissue models are imperative. Over the years, this realization has fuelled the development of
novel tools and platforms, which aim at capturing in vivo complexity. One example is the
field of biofabrication, which focuses on fabrication of three-dimensional (3D) biologically
functional products in a controlled and automated manner. Herein, we provide a general

overview of classical 3D cell culture platforms, particularly in the context of

neurodegenerative disease. Subsequently, the focus is put on bioprinting-based

biofabrication; its potential to advance 3D neuronal cell culture and, to conclude, the
relevant translational bottlenecks, which will need to be considered as the field evolves.
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Introduction
The vast majority of our current understanding of biological phenomena comes from routine
classical cell culture experiments; growing of cells onto flat and rigid two-dimensional (2D)
substrates. Even though these efforts have provided the research community with valuable
insights into the mechanisms underlying a variety of biological processes, it is nowadays
widely accepted that knowledge obtained from these studies might be too reductionist to
accurately translate to the human situation.[1,2] Growing cells onto 2D substrates deviates
significantly from the dynamic three-dimensional (3D) in vivo situation; cells lack tissuespecific polarity, have limited contact with neighbouring cells, and are exposed to nonphysiologically uniform diffusion kinetics, which together alter how cells perceive and
respond to their surrounding microenvironment (Fig. 1).

[3-5]

This discrepancy between

traditional in vitro culture conditions and the in vivo environment has been recognized among
a variety of research areas, including the area of neuroscience and more specifically
neurological disease, the latter presenting a great challenge in modern medicine. [6]
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Figure 1. Schematic representation of cells (a) cultured on a stiff 2D tissue culture substrate
and (b) embedded in a more physiologically relevant 3D hydrogel environment, which has
unique design variables (e.g. degradation sites and crosslinking mechanisms) that direct cell
behaviour. In vivo, cells reside in a complex and dynamic environment, which provides
binding ligands for cell adhesion and directs processes such as cell adhesion, proliferation,
migration, and morphology. Cells grown onto classical tissue culture substrates are confined
to a planar surface, which leads to abnormal integrin binding and (mechano) signalling
cascades, resulting in aberrant phenotypes. In the transition towards the third dimension,
hydrogel-based strategies play a pivotal role. Hydrogel matrices can be tuned to meet
application-specific requirements (e.g. degradation rate, porosity, and mechanical properties.
Adapted by permission from Macmillan Publishers Ltd: [NATURE METHODS] (7),
copyright (2016).

A glance at our nervous system
Our nervous system encompasses two main cell types, neurons and glial cells, which both
have a crucial role in nervous system functioning.[8,9] Neurons are highly polarized cells,
responsible for the transfer and processing of electrical and chemical signals that regulate
body function. According to their function, neurons can be classified into sensory neurons,
motor neurons, and interneurons, which can be excitatory, inhibitory or modulatory in their
effect. Typically, neurons consist of a cell body with projections, known as axons and
dendrites. These projections can vary in terms of number and position, which is highly linked
to neuronal function.[10] The non-neuronal glial cells come in a variety of subtypes and have
different roles in the development, maintenance, and functioning of the nervous system.[11]
For a long time, glial cells were regarded to have a relatively simple supportive function.
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However, research over the past years has uncovered their vital role and active participation
in the development and functioning of the nervous system. Beyond these cellular components
and their intricate communication, appropriate nervous system functioning requires a highly
regulated extracellular environment.[12] This dynamic mechanical and biochemical interplay
plays a key role in many essential processes, including spatio-temporal cell signalling, cell
identity, and cell function.[13-17] To gain more insights into neurological disorders and advance
current health care, it is essential to recapitulate this complex relationship between neurons
and their interaction with the surrounding environment, which requires more accurate in vitro
nervous systems models.

The rise of the third dimension
Over the years, various strategies aiming at capturing 3D tissue physiology have been
developed. Examples range from relatively simple approaches, such as the formation of
cellular spheroids, to more sophisticated scaffold-based approaches.[18-21] Whereas scaffoldfree approaches mostly rely on the inherent tendency of adherent cells to form aggregates,
scaffold-based approaches require a thorough consideration of a plethora of factors. Clearly,
the scaffold-based environment should mimic the native niche as closely as possible, which
calls for multidisciplinary expertise from biologist, engineers, and material scientists.
Unfortunately, accurately recapitulating the complex nature of tissues and/or organs by means
of traditional scaffold-based approaches remains challenging, especially when it comes to
achieving precise architectural configurations and spatial positioning of (multiple) cells and
scaffolding materials. To this end, the growing field of biofabrication offers an exciting
toolbox.[22,23] As described by Groll et al., the term biofabrication refers to the automated
generation of products with biological function by means of bioprinting or bioassembly and
subsequent maturation processes.[24] More specifically, biofabrication approaches encompass
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living cells, cell aggregates, bioactive molecules, and biomaterials to generate biologically
functional products in an automated and highly organized manner.
In this review, we focus on bioprinting-based biofabrication approaches and the potential to
advance currently available 3D cell culture platforms for nervous system applications,
particularly in the context of neurodegenerative diseases using Alzheimer’s disease as an
example. Noteworthy, here we refer to bioprinting as the use of printing technology to pattern
and/or organize biological entities in 2D or 3D as described by Derby.[25] After a brief
description of the general concept of 3D cell culture platforms, an introduction into the field
of bioprinting is provided. Subsequently, the potential of bioprinting technology and its
emerging applications for the nervous system will be discussed. To conclude, we highlight
possible translational bottlenecks, which will need to be addressed as the technology matures.
Key aspects include the necessary advances in converging disciplines, the need for
standardization in the field, and ethical regulations.

Neural tissue engineering: the need for relevant 3D cell culture platforms
Neurodegenerative disease is a collective term for a group of disorders which primarily affect
neurons.[26] Whereas a variety of disorders (e.g. Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease) are covered by this umbrella term, in this review the focus is put on
Alzheimer’s disease, which represents the most common cause of dementia among adults and
affects millions of people worldwide. As reported by the World Health Organization (WHO),
the number of people living with dementia is currently estimated at over 47 million, which is
expected to almost triple by 2050.
Alzheimer’s disease is clinically characterized by gradual deterioration in cognitive function,
including progressive memory loss, impaired judgment, and changes in personality and
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behaviour, which can become incapacitating at later stage of illness.[27-28] Besides the impact
on patients’ quality of life, dementia is a tremendous social and economic challenge; the
disease takes heavy toll on caregivers and has been identified as a major economic burden. [2931]

At the cellular level, Alzheimer’s disease is characterized by damage to cortical neurons,
particularly in the associative neocortex and hippocampus.[28,32] This neuronal damage is
correlated to deposition and accumulation of abnormal proteins; extracellular amyloid-β
peptides and intracellular filamentous hyperphosphorylated tau proteins, which are the core
hallmarks of Alzheimer’s disease and also known as plaques and tangles respectively.[33]
Whereas research was initially focused on neuronal cells and protein-mediated neuronal
damage, it has become increasingly apparent that Alzheimer’s pathogenesis has a more
complex nature and is not restricted to these events. Over the years research has evidenced
that other factors, such as immunological mechanisms, have an accompanying role in the
pathway leading to progression of the disease.[34] Despite progress in understanding the
underlying mechanisms and aspects of neurodegenerative disease, there are still many
unknowns. This is reflected by the lack of effective therapeutic options for the vast majority
of these disorders, including Alzheimer’s disease, which are nowadays limited to
symptomatic relief.[30,35] In order to advance the treatment of these disorders it is critical to
gain a deeper understanding of processes such as neural network formation, organization, and
functioning.

Classical 3D cell culture strategies
In response to the growing demand for more physiologically relevant models, a number of 3D
cell culture platforms have been developed.[36,37] Examples range from cell-self-assemblybased approaches, to scaffold-based approaches, and on-chip biomimicry. In the next section
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we aim to sketch and illustrate the importance of these classical 3D cell culture platforms and
capturing the third dimension.

Cell-self-assembly-based approaches
One of the most common cell-self-assembly-based approaches is the formation of cellular
spheroids (Fig. 2). Spheroid formation is generally considered to be a relatively simple 3D
cell culture method and has shown to be a convenient means towards more accurate tissue
models. The main benefit of using spheroids over 2D monolayer cultures is the presence of
more physiologically relevant diffusion gradients (e.g. oxygen and nutrients) and cell-cell and
cell-ECM interactions.[36,38,39] With time, a variety of methods have been developed to
produce spheroids, one well-known example being the hanging drop method.[36,38] In this
approach, aliquots of cell suspensions are seeded on an adherent surface, which is
subsequently reverted, yet allowing the droplets to stay attached due to surface tension,
resulting in gravity-enforced cell aggregation at the bottom of the droplets. Alternative
popular approaches are based on dynamic culture conditions (e.g. the spinner flask method),
low-adhesive surfaces (e.g. forced-floating technique), and more recently, micro-/nanopatterned surfaces and micromolding, the latter providing defined regions for cell
immobilization and subsequent spheroid formation.[38] All these different methods are
associated with their own advantages and disadvantages, resulting in spheroids of different
sizes and shapes, and should be chosen depending on the experimental needs and final
application.[36,39]

To date, spheroids have been successfully generated from a variety of cell types, including
neuronal cells.[40] For example, Dingle et al. generated neural spheroids from primary rat
cortical tissues by means of micromolding, which were reproducible in size and cellular
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composition.[41] Spheroid characterization revealed resemblance to in vivo cortical tissue in
terms of stiffness, neuronal electrophysiology, neural cell types, and morphology. Following
on from this study, Boutin et al. assessed the potential of this heterogeneous spheroid model
to form capillary-like networks, the later playing an important role in protecting the neuronal
environment.[42] Immunohistochemical analysis revealed that within three days, cortical
endothelial cells seemed to form networks in the spheroids, which were surrounded by
basement membrane components and relevant cell types. In future studies, this relatively
simple model could offer valuable insights in understanding disorders linked to neurovascular
dysfunction.

A more advanced cell-self-assembly-based 3D cell culture platform that has been gaining
increasing interest is the organoid model (Fig. 2).[43] Whereas various definitions are reported
in the literature, here we refer to organoids as self-organizing 3D cell clusters, which can be
established from different cell sources (e.g. primary cells, cell lines, stem cells), resembling
the tissue architecture of origin.[37,44,45] Over the last decade, organoid technology has made
tremendous progress and several in vitro organoids have been established.[37] Whereas the
relatively scarce amount of literature on neuronal organoids is mainly focussing on
neurodevelopmental phenomena, Raja et al. have shown its potential to study
neurodegeneration.[45] In this study, neural organoids were formed from induced pluripotent
stem cells derived from Alzheimer’s disease patients. This organoid model has shown to be
robust, able to recapitulate both hallmarks of Alzheimer’s disease, and has been shown to be
amenable to experimental manipulation in terms of drug treatment.
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Figure 2. Cell culture platforms: monolayer culture on conventional tissue culture substrates,
single cell in 3D matrix, spheroid culture, and organoid culture. Obtained and modified
from[42] with permission from Elsevier.

Biomaterial-aided 3D cell culture platforms
In this section, we only focus on the non-biofabrication biomaterial-aided platforms that
involve either pre-fabricated scaffolds for cell cultivation or polymer hydrogels for cell
encapsulation. In both cases, the biomaterials do not only provide structural and mechanical
support, but also guide the cells via acting as a template for tissue formation.[20,47,48]
Intuitively, these biomaterials should resemble the dynamic native microenvironment of the
specific target tissue as closely as possible, a task that can be extremely challenging; it does
not only require the biological and functional integration of the cells with the surrounding
biomaterial(s), but also careful consideration of biodegradability, mechanical properties,
scaffold architecture, and manufacturing technology.[47,49]

Over the years, a myriad of materials have been investigated for their potential to support
neuronal 3D cell culture.[50] These range from natural polymers (e.g. collagen, hyaluronic
acid, alginate, Matrigel, and silk) and synthetic polymers (e.g. poly(lactide-co-glycolide
(PLGA), poly-L-lactic acid (PLLA), and polyurethane (PU)) to hybrid materials, metals,
ceramics, glass, and carbon nanotubes. For example, Frampton et al. described a 3D culture
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system based on cell entrapment in peptide-functionalized alginate hydrogels.[51] Cell viability
and functional analysis of primary rat glial and neuronal cells demonstrated appropriate cell
viability and metabolic function within the constructs over a period of 14 days. Interestingly,
cell morphology, particularly of astrocytes differed from cells cultured on 2D substrates.
Analysis of the functional activity of primary rat neurons showed formation of functional
synaptic elements and electrical activity. Together, the results showed that this system could
offer a viable cell culture platform to (co-)culture a variety of relevant cell types for use in
neural cell culture, supporting cell type-specific function. Lai et al. compared neuronal
voltage gated calcium channel functionality in 2D to 3D setting.[52] Primary neuronal cells
were harvested from mice and either cultured onto 2D flat surfaces or in 3D synthetic
polymer scaffolds, the latter consisting of PLLA and polystyrene. It was found that cells in
3D scaffolds resembled native intact tissue more closely in terms of cell morphology and ion
channel functioning. Another striking example that illustrates the importance of recapitulating
an in vivo-like 3D cellular environment is described by Choi et al. who studied the pathogenic
mechanisms of Alzheimer’s disease in a 3D Matrigel-based brain tissue-like environment.[53]
Whereas amyloid-β is thought to diffuse into the culture medium in 2D systems and to be
removed during regular media changes, it was found that this closed 3D culture model system
promoted amyloid-β aggregation, thereby more closely recapitulating Alzheimer’s disease
pathology. More recently, Kraus et al. developed a spheroidal co-culture model to examine
neurite formation.[54] In this study, spheroids were formed from glial cells (i.e. Schwann cells)
and neurons and subsequently encapsulated in a 3D collagen matrix. Evaluation of neurite
lengths demonstrated a significant increase in neurite length after a period of seven days in
the 3D set-up compared to 2D culture.

Organ-on-a-chip technology
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Organ-on-a-chip technology refers to microfluidic cell culture devices, which are designed to
reconstitute critical tissue- and organ-level functions and rely on a sophisticated interplay
between engineering and biology.[55,56] These systems are used for and offer control over a
variety of key system parameters, including the choice of cells and their spatial positioning.
However, the added value of on-chip biomimicry lies within its potential to control
parameters that are not easily controlled in 3D static cultures or bioreactors (e.g. fluid flow,
physical and chemical gradients), which makes them promising tools to address fundamental
questions in the area of tissue development, organ physiology, and disease etiology.[56]

Over the years, various microfluidic devices have been developed to provide insights into the
pathophysiology of neurodegenerative disorders.[57] For example, Choi et al. and Cho et al.
utilized a microfluidic-based approach to investigate the effects of amyloid-β (aggregation) on
neurons and microglia respectively.[58,59] In their study, Choi et al. used a low-flow
microfluidic system to assess the neurotoxicity of time-dependent amyloid-β aggregation and
the effect of physiological flow on neuronal cell survival.[58] With their microfluidic platform,
Cho et al. studied the effect of amyloid-β on microglial accumulation, which demonstrated a
different role for soluble and bound amyloid-β during microglia recruitment and
localization.[59] Another well-reported topic involves amyloid-β and tau protein propagation.
Kunze et al. have utilized a microfluidic device to study the neurodegenerative propagation
processes of Alzheimer’s disease.[60] Primary rat cortical neurons were cultured in two
separated

cell

compartments,

one housing diseased

neurons

(i.e.

showing tau-

hyperphosporylation) and the other healthy neurons. By designing the microfluidic device in
such a manner that connectivity was favoured through neurite outgrowth from both
compartments over time, a co-pathological state within the same neural cell culture was
established. More recent studies regarding amyloid-β and tau protein propagation are
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presented by Song et al. who demonstrated amyloid-β spreading via neuronal connections
along axonal membranes[61], Deleglise et al. who investigated the distant effects of local
amyloid-β stress on neuronal subcompartments and networks[33], and Dujardin et al. and
Calafate et al. who offered novel insights into tau protein transfer.[62,63]

Bioprinting
3D cell culture platforms provide the target tissues with a (temporary) microenvironment and
thereby contribute to spatio-temporal cell signalling, cell identity, and cell function. Although
these 3D cell culture platforms have been demonstrated to offer a promising route towards
more physiologically relevant neuronal models and in-depth understanding of cellular
behaviour and pathological conditions, there are still a number of limitations. One of the
primary general challenges is related to the lack of adequate control. Regardless of the
platform, issues such as irregular geometry (e.g. external shape and internal architecture of the
scaffolds) and size, poor reproducibility, and difficulties regarding scaling-up impede their
widespread use. To this end, bioprinting offers an exciting opportunity. By combining
biomaterials, cells, and/or growth factors (composites referred to as bioink) with automated
fabrication processes such as additive manufacturing (the generation of 3D constructs in a
layer-by-layer manner based on a computer-aided design (CAD)), it facilitates the generation
of 3D bio-engineered constructs with superior organization and more closely resembling
native tissues.[22,23,24] This computer-controlled deposition of biologically relevant materials
allows the fabrication of (multi)-cellular constructs. Besides, the layer-by-layer architecture
allows tailoring beyond the cellular level, namely in terms of materials, and biochemical cues,
which could be optimized to meet cell-specific requirements. In this manner, multiple cell
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types could be contained throughout a single 3D construct, yet in an environment optimized
for each of the individual components.

Bioprinting technologies
Although a wide variety of bioprinting technologies have been described in the literature,
three main categories can be distinguished; inkjet printing, laser-assisted printing, and
extrusion-based printing (Fig. 3).[64,65]

Figure 3. Main bioprinting technologies: (a) Inkjet printing, (b) Laser-assisted printing (c)
Extrusion printing. Figure obtained and modified from

[23]

with permission from John Wiley

and Sons.

Inkjet printing can be described as a noncontact printing process in which controlled volumes
of (bio)ink (1–100 picolitres; 10–50 μm diameter) are dispensed on predefined locations,
driven by thermal or piezoelectric forces (Fig. 3(a)). Both in thermal inkjet printing and
piezoelectric inkjet printing, (bio)ink droplets are forced from the nozzle by creating a
pressure pulse. In thermal inkjet printing, this pressure pulse is generated by heating. This
heating results in vaporization of small volumes of the (bio)ink, producing the pulse required
13

to expel material from the nozzle. Piezoelectric inkjet printing involves the application of a
direct mechanical pulse to the (bio)ink, which on its turn generates the pressure needed to
force material though the nozzle. Regardless of the high resolution, relatively low cost, and
wide availability of inkjet printing, several factors impede its successful widespread
application.[23,65] These include the challenges regarding cell viability due to the small
orifices, the potential risks of exposing the (bio)ink to thermal and mechanical stress,
inconsistency in droplet size, nozzle clogging when using biologically relevant cell densities
(>106 cells/ml), and the low upper viscosity limit of the (bio)ink (ideally < 10 mPa/s), which
although considered to be beneficial for cell migration, proliferation, and cell viability,
influences printing fidelity.[23,65]

As the name indicates, laser-assisted printing encompasses a plethora of manufacturing
technologies which utilize a laser to deposit (biological) materials on a substrate. Laserassisted bioprinting stems from the principles of a subclass of laser-assisted printing, namely
laser-induced forward transfer (LIFT) (Fig. 3(b)). In LIFT approaches, a focused laser-source
is used to transfer material from a so-called donor slide towards the receiving substrate.
Typically the donor slide is covered with a laser energy absorbing layer and the desired
(bio)ink. The focused laser pulse causes evaporation of the absorbing layer, leading to the
formation a high-pressure bubble, which induces propulsion of the material. As this approach
is nozzle free, the clogging issue associated with inkjet-based printing or extrusion-based
printing is avoided. In addition, laser-assisted printing is compatible with materials with a
broad range of viscosities (1–300 mPa/s) and able to deposit cells at medium cell density (i.e.
108 cells/ml) without detrimental effects on cell viability.[23,64,65] Despite these advantages, the
presence of metallic residues in the final construct, the challenging and time-consuming
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nature of preparing individual ribbons, and relatively high costs are several examples of
hurdles yet to clear.

Nowadays, most of the commercially available bioprinters are based on extrusion-based
dispensing (Fig. 3(c)). These systems function by robotically controlled extrusion of the
(bio)ink, which is usually driven by mechanical action (piston or screw) or a pneumatic
system, each posing their own (dis)advantages. Whereas mechanically driven deposition
usually provides more control over the material flow, pneumatic systems have simpler drivemechanism components, the latter allowing for higher maximum force capabilities. In
contrast to inkjet printers, which yield single droplets of material, extrusion printers yield
continuous filaments of the (bio)ink, usually with a resolution in the order of 200 µm.
Besides, extrusion printing is compatible with materials with a wide range of viscosities (30 –
6×107 mPa/s). Even though the resolution is substantially lower when compared to laser- or
inkjet-based systems, the fabrication speed, clinically relevant sizes, and ability to deposit
high cell densities (>108 cells/ml) with high cell viability make this technology very
promising for tissue engineering and regenerative medicine (TERM) applications.[23,65]

Bioprinting in 3D neuronal cell culture
Given that the field of bioprinting in general, and even more for this specific application, is
still in its infancy, early studies of bioprinting in 3D neuronal culture have been focused
mostly on healthy tissue. However, even though these studies do not directly concern diseased
tissue(-like) constructs, these could be used as tool for a variety of applications, ranging from
cell behaviour studies to understanding pathological conditions and drug testing, which is
related to and relevant for neurodegenerative disease.
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Various studies relating to this topic have been reported. Among these, several have been
focussing on the effect of printing processes on cell viability. For example, Xu et al. and Xu
et al. studied the delivery of neuronal cells by a modified thermal inkjet printer, and
demonstrated no significant effect on cell survival.[66,67] More recently, Lorber et al. studied
the potential of inkjet printing of adult rat retinal ganglion cells and retinal glia, demonstrating
no significant difference in cell survival compared to non-printed controls.[68] In a similar
approach, Tse et al. printed primary porcine Schwann cells and neuronal analogue NG108-15
cells with a piezoelectric inkjet printer.[69] This study showed that a higher range of
experimental voltages has no adverse effects over a period of seven days. Whereas these
studies could be considered relatively simplistic in nature (i.e. printing of cells to explore
compatibility with the printing modality) these efforts have illustrated that relevant cells can
be delivered and positioned by means of inkjet printing approaches without substantial
damage.
A major advantage of bioprinting approaches is the ability to deliver and distribute cells and
other biological factors in a very precisely controlled manner. An example is given by Lee et
al. who fabricated cell–hydrogel composites for the purpose of in vitro neural culture.[70]
Murine neural stem cells were deposited on top of a layer of printed collagen, subsequently
crosslinked to immobilize the cells, and covered with an additional layer of collagen.
Standard cell viability and proliferation assays showed that the printing technique did not
affect cell viability. To explore the effect of growth factor release, a VEGF-releasing fibrin
gel was added to the system. Whereas further studies should be conducted, initial experiments
have shown that cellular proliferation and migration was supported over time. In a more
advanced approach, Hsieh et al. explored bioprinting of cell-laden thermo-responsive
biodegradable PU hydrogels.[71] Murine neural stem cells were harvested from adult mouse
brain, encapsulated in different PU hydrogels, and subsequently bioprinted, forming a grid-

16

like structure. Cell viability, proliferation, and gene expression analysis demonstrated its
potential as a suitable niche for neuronal stem cell proliferation and differentiation.
Furthermore, the potential of this strategy in central nervous repair was evaluated in zebrafish
and embryo neural injury models, which demonstrated its potential to rescue central nervous
system functioning. Whereas the above-mentioned approaches illustrate the potential of
bioprinting technology for neuronal applications, these fabricated constructs are mainly
constricted to relatively thin layers of cells within cell culture media or on top of a hydrogel.

Given that the utility of actual bioprinting platforms for this particular application is at early
stage, only a few studies have been reported in literature. One example is presented by our
group and involves the development of a novel bioprinting-based method to recapitulate the
layered structure of the brain and thereby fabricate 3D brain-like structures.[72] This study was
based on previous work by Tang-Schomer et al., who developed compartmentalized 3D
brain-like cortical tissue with silk fibroin-based biomaterials.[17] Our group developed an ArgGly-Asp (RGD) peptide-modified gellan gum-based bioink (RGD-GG), which was assessed
in terms of neural cytocompatibility, network formation, and printability. Discrete layers of
cell-encapsulating (i.e. mouse primary neurons) RGD-GG were deposited using a simple
hand-held printing device, resulting in layered constructs (Fig. 4(a-e)). Standard
calcein/propodium iodide assays revealed acceptable cortical neuron and glial cell viability,
both after encapsulation and printing RGD-GG. Immuno-staining seven days after
encapsulation demonstrated neuronal network formation throughout the RGD-GG structures.
To assess the potential of this strategy to create more complex multi-layered brain-like
structures, six-layer structures were printed. Visual analysis revealed presence of distinct
layers, within the solid structure. To assess the neural cytocompatibility of these larger
structures, a three-layer construct was printed, consisting of two cell-laden RGD-GG layers,
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separated by an acellular RGD-GG layer. Neuronal network formation was observed after
five days of culture, with axons starting to penetrate into the acellular middle layer (Fig. 4(fg)). These multi-layer brain-like structures have shown to provide an environment in which
the dynamic process of neural growth can be observed and quantified in 3D and thereby offer
a promising tool for a variety of applications ranging from cell behaviour studies to
understanding pathological conditions and drug testing.

Figure 4. Layered brain-like structure: (a) SolidWorks schematic of the envisioned six-layered
construct, (b-e) construct fabrication process, in which each colour represents a distinct layer,
(f) confocal microscope images of the neurons coloured for their z-axis distribution after 5
days of culture, (g) showing neurite penetration through the gel into the acellular RGD-GG
layer. Scale bars represent 100 μm. Figure obtained and adapted from [72] with permission
from Elsevier.
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In another approach towards establishing more accurate neuronal tissue-like structures, our
group investigated in situ differentiation of human neural stem cells in bioprinted
constructs.[73] Frontal cortical human neural stem cells were encapsulated in an optimized
polysaccharide bioink consisting of alginate, carboxymethyl-chitosan, and agarose, and
followed by a micro-extrusion approach. Characterization of the cells revealed homogenous
cell distribution and high viability throughout the printed construct. Immunophenotyping and
reverse-transcription quantitative PCR (RT-qPCR) analysis demonstrated successful
differentiation into functional neurons and supporting neuroglia, illustrating the potential of
this platform to be used in translational studies.
Following on from this study, Gu et al. described the first example of bioprinted human
induced pluripotent stem cell constructs, which were successfully differentiated into
homogenous neural tissues.[74] Human induced pluripotent stem cells were encapsulated in a
bioink consisting of alginate (5% w/v), carboxymethyl-chitosan (5% w/v), and agarose (1.5%
w/v) and subsequently bioprinted (Fig. 5(a)). Extrusion printing of the cell-laden bioink
resulted in homogenous cell distribution throughout the constructs, with negligible cell death
over a period of seven days, which was determined by standard calcein/propodium iodide
assays (Fig. 5(b)).[74] Flow cytometry studies, performed after ten days in culture, revealed
expression of pluripotency markers, which was further confirmed by induction of embryoid
bodies. The bioprinted stem cells were then differentiated into cells with phenotypes that
represent neuronal subtypes and microglia, as confirmed by immunophenotyping and RTqPCR. This study has successfully demonstrated the ability to produce human induced
pluripotent stem cell-laden constructs and differentiate these into relevant cell types, which is
an important step towards bioprinting-based neuronal tissue models.
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Figure 5. Bioprinting of human induced pluripotent stem cells: (a) schematic representation of
the approach, in which the bioink is prepared by adding the cells to an optimized alginate,
carboxymethyl-chitosan, and agarose (Al-CMC-Ag) mixture and subsequently bioprinted.
Cell viability studies by means of calcein/propidium iodide staining have shown (b)
homogenous cell distributions and high cell viability over a period of seven days postprinting. Scale bars represent 1 mm. Figure obtained and adapted from [74] with permission
from John Wiley and Sons.

Bioprinting, a complementary approach
The true power of bioprinting technology lies in its superior potential to offer spatial and
temporal control in a reproducible manner. However, it is important to realize that different
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applications may require a different approach, which could be offered by other 3D cell culture
platforms. Therefore, rather than being considered as superior, it is noteworthy to mention the
complementary role of bioprinting technology, when being integrated with other existing 3D
cell culture platforms.[75] Several papers have been reported regarding the integration of
scaffold-free 3D cell culture platforms in combination with 3D printing technology. For
example, Mironov et al. have demonstrated the potential of bioprinting to precisely deposit
tissue spheroids formed from human dermal fibroblasts according to predefined patterns.[76]
Very recently, Schneeberger et al. have reviewed the convergence of organoids and
bioprinting technologies, highlighting the benefits bioprinting could have in terms of
increasing the (clinical) application potential of organoids.[45]

Besides its added value for scaffold fabrication, additive manufacturing could facilitate the
development of custom-made microfluidics devices.[77] For example Johnson et al. used
additive manufacturing technology to fabricate a nervous system-on-a-chip.[78] This
biomimetic chip consisted of three chambers with separate fluid environments and
microchannels, the latter providing axonal guidance and alignment (Fig. 6). The different
compartments were loaded with appropriate cell types and the complete chip was studied over
time in terms of cell organization and its potential to be applied in viral infection assays.
Whereas spatial separation was indeed achieved, axonal networks were able to penetrate into
the chambers, allowing axon-to-cell integration between compartments. In line with this,
analysis of axon-to-cell spreading of viral particles from one compartment to another
demonstrated biological connectivity between the compartments. In this approach, relevant
cell types were successfully integrated on their chip, illustrating that additive manufacturing
could be an effective fabrication approach for the development of tailor-made on-a-chip
biomimicry devices.
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Figure 6. 3D printed nervous-system-on-chip: (a) schematic of the printing approach, which
consisted of three consecutive steps. First, microchannels providing axonal guidance were
printed, subsequently, a sealant layer was printed, after which the individual chambers were
fabricated. The chip was completed by (b) functionalizing the chambers with the relevant cell
types. Obtained and modified from [78] with permission of The Royal Society of Chemistry.

Future perspectives: challenges and opportunities
Over the years, bioprinting technology has shown to offer great potential to establish 3D
tissue-like constructs and thereby approximate in vivo like conditions. Even though
bioprinting technology and its implications for the nervous system are still in its infancy,
several important challenges that remain to be addressed are already identified: 1) systematic
studies of cell-material and cell-ECM interactions in 3D to enable optimization of bioink
formulations and scaffold design, 2) improved characterization methods to monitor the
dynamic process of neural growth in 3D, such as tracking of cell migration and
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differentiation, 3) coupling of high throughput screening methodologies with 3D printed
neural systems for fundamental studies and pharmacological tests.
Given its potential, research is increasingly turning to biofabrication technology to fabricate
3D functional constructs. However, it is essential to bear in mind that biofabrication
represents an integrated group of enabling technologies and disciplines, which together have
as a common goal to develop biologically functional products.[24,79] As the biofabrication field
matures, developments within all these converging technologies and disciplines become
equally important and will need to be streamlined in order for the field to advance.

The importance of converging disciplines
Central to the biofabrication approach is the software, which is the starting point for construct
design and drives the transition from this design phase to actual printing.[80] The software
forms the basis for the quality and usability of the final construct, and should cover construct
design and machine control in a user-friendly manner. It is essential to develop the software
as well as the hardware, which can keep up with our enhanced understanding and appreciation
of biofabrication-based tissue engineering and associated disciplines (e.g. the need for
multiscale geometric complexity and multimaterial management).

Another crucial pillar for the development of the biofabrication arena is the field of materials
science. Key in the biofabrication discipline is the choice of the bioink. Regardless of the final
application, this bioink should meet various general requirements, two crucial ones being its
biocompatibility and printability. On the one hand, the bioink should resemble the native in
vivo niche as closely as possible, which requires careful consideration of cellular behaviour,
cellular functions, and -depending on the application- host integration. On the other hand, the
bioink should exhibit appropriate viscous and mechanical properties, which enable accurate
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deposition and shape-maintenance post-printing. Even though the scope of printable materials
is expanding, to date, meeting both the requirements is hard to achieve, and usually involves a
suboptimal, yet tolerable balance between both factors.[81] In order to advance the field, it is
essential to develop more advanced biomaterials, which meet application-specific
requirements. A relevant and exciting development is the emerging field of four-dimensional
(4D) bioprinting, which is based on 3D bioprinting, but incorporates an extra fourth
dimension in the form of ‘time’ to the system. 4D bioprinting goes hand-in-hand with
developments in the area of smart stimuli-responsive materials.[82,83] These materials can be
defined as materials that undergo a change in shape and/or function in response to an external
stimulus such as temperature. Together, this facilitates the fabrication of constructs that can
evolve over time after being printed, which makes it possible to add another level of
complexity to the fabricated constructs, more closely resembling dynamic tissue
conformations.
Whereas the above-mentioned challenges are mostly centred on the pre-printing and printing
phase, it is important to anticipate on post-printing issues. One important, yet limiting aspect
is related to the lack of optimized methods to analyse and assess the more complex 3D
structures. For decades, research was predominantly focussing on thin, optically transparent
2D culture platforms, not only in terms of experimental design, but also in terms of
subsequent data analysis. Whereas the increasing in vivo relevance that is offered by 3D cell
culture platforms has its benefits, data interpretation becomes more challenging and requires
developments in imaging technologies and establishing standard protocols.
In order to bring biofabrication-based innovation from the bench to the clinic, it is not only
necessary to look into the scientific and technical aspects, but also to look beyond. Key
aspects to consider are the need for standardization in the field and the ethical considerations.
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The need for standardization
Among the abundant literature describing biofabrication and biofabrication approaches, a
variety of ambiguous terms exist. [84,85] For example, terminology to describe the technology
ranges from 3D printing, to bioprinting, additive manufacturing, additive biomanufacturing,
and biofabrication, which are used interchangeably, often without being appropriately
defined. This way of reporting could lead to potential confusion and makes it challenging to
find relevant literature and compare results, which hinders knowledge transfer.
If the field is to move forward, it is not only essential to establish standards in terms of
terminology, but also in terms of experimental design, procedures, and performance. In this
context, it is essential to develop a regulatory framework, which accounts for the potential of
biofabrication technology to create tailor-made products that are integrated with living cells.
As described in detail by Hourd et al. points of consideration do not only arise around testing
and validation of these customizable products, but already at the stage of experimental
design.[84] For example, successful implementation requires sufficient knowledge of the
materials in terms of cytocompatibility, which indeed influences performance, but also on its
reaction

when

subjected

to

the

printing

process

and

to

its

post-printing

conditions/environment. One should take into account that it is not only about a relatively
novel manner of manufacturing, but also about a complex product, with the potential to be
placed in a dynamic environment. The true challenge lies in developing a regulatory
environment in which products pass a set of standards and regulations, while retaining the
customizable nature and ability to fabricate patient-specific products.

Ethical considerations
Whereas the biofabrication arena has substantial similarities with the fields of regenerative
medicine and tissue engineering, the unique character of biofabrication technology and its

25

potential applications necessitates thorough biofabrication-specific ethical considerations.[8688]

These involve questions related to the novelty of the technology itself, but also regarding

its integration with biological products (e.g. stem cell technology). In addition, seen from a
translational-application point of view, the great benefits that 3D biofabricated tissue products
could offer in terms of personalised treatments raise their own ethical questions. From a
preclinical ‘bench-side’ perspective, questions mainly arise around the use of animal and
human materials. Several topics of debate are the choice and use of animals, use of cells
sourced from embryonic and fetal tissues, and the privacy-related concerns associated with
biobanking.[87,88] Other factors worth to consider include data integrity and appropriate study
design, which could prevent premature transition from the bench to the bedside stage.[86] This
bedside stage, which involves clinical trials, predominantly addresses questions related to the
participants; selection of participants, and most importantly, the risks for the participant,
which should be appropriate compared to the potential benefits on the larger scale. Lastly,
there are society-related ethical considerations, which include the public’s perception of the
biofabrication field. As with any emerging technology, this perception is highly influenced by
the public media. To make scientific developments more accessible to the general audience,
complex findings are usually presented with excessive enthusiasm, giving weight to particular
aspects of the topic. Given the multidisciplinary character and unknown risks of
biofabrication technology, biofabricated products, and their possible applications, it may be
difficult to look beyond the hype. However, it is crucial to realize that the manner of reporting
affects the public’s view on science. Overselling could easily lead to false expectations,
disappointment, and eventually distrust in researchers and the technology. Sufficiently
informing the public is essential for appropriate general understanding of science and could
help when leading discussions on related topics (e.g. the role of biofabrication on human
enhancement).
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Conclusion
The vast majority of our understanding of neurological disorders is based on simplified 2D
cell culture experiments; an environment that profoundly differs from the dynamic native in
vivo situation. To gain a better understanding of our nervous system, the associated disorders,
and to develop effective therapeutics, more accurate and meaningful models are imperative.
As discussed, bioprinting-based biofabrication approaches offer the potential to more
accurately recapitulate tissue features. These models are envisioned to shed new light on the
causes and the mechanisms underlying (neurodegenerative) diseases and improve and
accelerate the translation of in vitro findings to clinically relevant applications. However, one
should realize that biofabrication encompasses a variety of disciplines, requiring constructive
collaboration between engineers, scientists, and clinicians. Successful implementation of a
novel biotechnology such as biofabrication requires scientists to look beyond experimental
design, keep the final application in mind, and consider the interplay between their research
and associated (potential) ethical and regulatory issues.
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